North America Interventional Radiology Products Market Outlook, 2025-2035
The North America Interventional Radiology Products Market is poised for significant growth between 2025 and 2035, driven by rapid technological advancements, increasing prevalence of chronic diseases, and growing adoption of minimally invasive procedures. This sector encompasses a wide range of products including angioplasty balloons, stents, catheters, embolization devices, and imaging modalities. Companies are investing in R&D for advanced solutions tailored to both hospital and outpatient settings. The integration of AI, telehealth, and improved imaging techniques is setting new standards, while the region benefits from robust healthcare infrastructure, favorable reimbursement, and strong presence of global vendors.
Latest Market Dynamics
Key Drivers
- Rising prevalence of cardiovascular and oncological conditions propelling demand for minimally invasive interventional radiology solutions, highlighted by Boston Scientific's launch of next-gen angioplasty balloons in early 2024.
- Ongoing advancements in imaging technology—such as Siemens Healthineers’ AI-enhanced CT and ultrasound-based guidance systems—enabling greater precision and operational efficiency in interventional procedures.
Key Trends
- Widespread adoption of AI-powered image processing and robotic-assisted interventional platforms, with Philips Healthcare debuting its smart workflow solution in June 2024.
- Movement towards outpatient and ambulatory surgical centers leveraging adaptable, compact interventional radiology devices, evidenced by the launch of Medtronic’s portable cath-lab solution in 2024.
Key Opportunities
- Expansion of tele-interventional services and remote diagnostics enabled by robust digital infrastructure and recent rollouts by GE Healthcare, which announced a new cloud-based interventional management platform in July 2024.
- Accelerating partnerships between device makers and healthcare networks; recently, Terumo Corporation entered a strategic alliance with North American hospital systems to co-develop customized vascular access solutions.
Key Challenges
- Stringent regulatory requirements impacting new device approvals, as reported by Abbott Laboratories facing extended review times for novel embolization products in Q2 2024.
- Shortage of highly trained interventional radiologists, leading to workflow bottlenecks, particularly in rural U.S. and Canada regions, as outlined by a Stryker Corporation market access report in June 2024.
Key Restraints
- High upfront costs for advanced imaging modalities and devices limiting reach across smaller healthcare facilities, a trend confirmed by Merit Medical Systems’ 2024 cost pressures analysis.
- Data privacy and cybersecurity concerns over interconnected systems, highlighted following a 2024 data breach incident affecting a number of U.S. diagnostic centers equipped with networked Philips platforms.
Market Share by Type, 2025
Catheters dominate the North America Interventional Radiology Products Market in 2025, reflecting their versatility and frequent use in diverse applications. Angioplasty stents and balloons follow closely, owing to rising cardiovascular interventions. With continuous innovations in IVC filters and embolization devices, there's notable growth in these segments. Biopsy needles also play a critical role as cancer diagnostics expand. The market landscape remains dynamic as device miniaturization and multi-functionality gain traction.
Market Share by Application, 2025
Cardiology remains the top application segment for interventional radiology products in North America in 2025, representing nearly a third of total usage. Oncology is rapidly gaining ground, fueled by increasing minimally invasive tumor ablation and biopsy procedures. Significant growth is also observed in urology & nephrology and neurology owing to new device launches targeting complex interventions. The convergence of technological improvements and multi-disciplinary collaboration is broadening the scope of interventional radiology across specialties.
Market Revenue (USD Million), 2020-2035
The market witnessed a substantial uptick in revenue from 2020 through 2025, growing from 4250 million in 2020 to 6480 million in 2025, with projections set to surpass 13,500 million by 2035. Year-on-year growth is propelled by increased procedure volumes, rapid device innovation, and the enhanced reimbursement environment. The outlook remains robust, as continued product launches and expansion into ambulatory care settings are further expected to drive market size through the forecast period.
Market Year-on-Year Growth (%), 2020-2035
Year-on-year (YOY) growth in the North America Interventional Radiology Products Market remains strong, averaging between 7-8% from 2020 to 2025. Growth rates peak during 2025-2030 at 8.5%, followed by a slight stabilization. This robust YOY momentum is underpinned by greater chronic disease prevalence, policy support for outpatient interventions, and consistent advancement of device efficacy. Market maturity is anticipated past 2030, leading to moderate, sustainable expansion.
Market Share by Region, 2025
The United States commands the lion’s share of the North America market in 2025, accounting for three-quarters of total revenue, fuelled by superior healthcare infrastructure, innovation, and reimbursement. Canada holds a significant share, driven by increasing adoption of advanced interventional protocols, while Mexico shows accelerated growth thanks to improvements in public and private healthcare investment. Regional disparities are expected to diminish as technology penetration deepens.
Market Share by Players, 2025
Siemens Healthineers, GE Healthcare, and Philips Healthcare collectively account for a dominant portion of the market due to their broad portfolios spanning both devices and imaging solutions. Boston Scientific and Medtronic are notable contenders in device innovation. Market consolidation and intensifying competition among established players ensure steady advances in product efficacy, customization, and support services by 2025.
Market Share by Buyers, 2025
Hospital pharmacies and large-scale healthcare networks remain the primary buyers of interventional radiology products in 2025, holding a majority share, followed by retail pharmacies and an increasing share composed by online and direct tenders, aligned with the shift to digital and value-based procurement models. This distribution reflects direct alignment with procedural volumes and the push towards integrated healthcare purchasing approaches.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 6480 |
| Regions | United States, Canada, Mexico |
| Segments | Angioplasty Balloons, Angioplasty Stents, Catheters, Inferior Vena Cava (IVC) Filters, Embolization Devices, Biopsy Needles, Cardiology, Oncology, Urology & Nephrology, Gastroenterology, Neurology, Others, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Distributors & Wholesalers, Others, X-ray, Ultrasound, CT, MRI, Fluoroscopy, Others, Small, Medium, Large |
| Players | Siemens Healthineers, GE Healthcare, Philips Healthcare, Boston Scientific Corporation, Medtronic, Stryker Corporation, Terumo Corporation, Merit Medical Systems, Becton Dickinson and Company, Cook Medical, C.R. Bard, Abbott Laboratories, Canon Medical Systems, Alphenix (Canon), AngioDynamics |
Key Recent Developments
- July 2024: GE Healthcare launched a next-generation digital interventional management platform supporting remote-guided procedures across North America.
- June 2024: Philips Healthcare introduced AI-powered image fusion capabilities for vascular interventions, further enhancing real-time guidance and workflow.
- July 2024: Terumo Corporation formalized a partnership with three leading U.S. hospital systems to co-develop custom vascular access kits.
- June 2024: Medtronic received FDA clearance for its portable cath-lab suite, optimized for ambulatory surgical centers.
- June 2024: Boston Scientific announced FDA approval and rollout of its innovative, drug-eluting peripheral angioplasty balloon in the U.S. market.
